MICHAL FYDA: Open Payments
NPI 1356106272 · TAMPA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,970 in 39 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $33 · 2025 $3,970
Food & beverage: $3,970
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $702 |
| Otsuka America Pharmaceutical, Inc. | 10 | $601 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $367 |
| Axsome Therapeutics, Inc. | 3 | $366 |
| Janssen Pharmaceuticals, Inc | 3 | $347 |
| E.R. Squibb & Sons, L.L.C. | 3 | $338 |
| Lundbeck LLC | 2 | $265 |
| Alkermes, Inc. | 2 | $244 |
| Vanda Pharmaceuticals Inc. | 2 | $224 |
| JAZZ PHARMACEUTICALS INC. | 1 | $146 |
Products named: REXULTI, VRAYLAR, CAPLYTA, Auvelity, COBENFY, FANAPT, SPRAVATO, INVEGA SUSTENNA.
Industry payments across FL — which companies pay providers there.
